Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Regulation of Sodium and Potassium01:26

Regulation of Sodium and Potassium

The regulation of sodium and potassium ion concentrations in the human body is a complex process governed primarily by hormones such as aldosterone, antidiuretic hormone (ADH), and atrial natriuretic peptide (ANP).
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily in...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Content and delivery preferences for information to support the management of high blood pressure.

Journal of human hypertension·2022
Same author

ARMC5 is not implicated in familial hyperaldosteronism type II (FH-II).

Journal of human hypertension·2017
Same author

Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea.

Journal of human hypertension·2017
Same author

JHH change in leadership.

Journal of human hypertension·2015
Same author

Waiting a few extra minutes before measuring blood pressure has potentially important clinical and research ramifications.

Journal of human hypertension·2013
Same author

Response to 'More fuel in the obesity paradox debate': fatness, fitness, stiffness and blood pressure.

International journal of obesity (2005)·2012
Same journal

Patient out-of-pocket costs for antihypertensive single pill combination products with cost caps.

Journal of human hypertension·2026
Same journal

Mindfulness based interventions for blood pressure reduction: systematic and umbrella review of existing meta-analyses.

Journal of human hypertension·2026
Same journal

Invasive observation of reactive systolic blood pressure responses to upper-arm cuff inflation.

Journal of human hypertension·2026
Same journal

Association between post-thrombectomy blood pressure trajectories and clinical outcomes in hypertensive patients with acute ischemic stroke: a retrospective cohort study.

Journal of human hypertension·2026
Same journal

Systemic inflammation indices generated from first-trimester blood tests can be potential biomarkers for predicting preeclampsia.

Journal of human hypertension·2026
Same journal

Chronotherapy in hypertension: a systematic review and meta-analysis of antihypertensive dosing timing on cardiovascular outcomes.

Journal of human hypertension·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta
08:08

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta

Published on: June 10, 2015

Salt, aldosterone and hypertension.

E Pimenta1, R D Gordon, M Stowasser

  • 1Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Princess Alexandra and Greenslopes Hospitals, Brisbane, Queensland, Australia.

Journal of Human Hypertension
|July 13, 2012
PubMed
Summary
This summary is machine-generated.

Aldosterone and salt independently and jointly contribute to hypertension and cardiovascular disease. Reducing salt intake or blocking aldosterone can mitigate these harmful effects and potentially decrease salt appetite.

Related Experiment Videos

Last Updated: May 20, 2026

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta
08:08

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta

Published on: June 10, 2015

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Aldosterone and dietary salt intake are independently linked to hypertension, cardiovascular morbidity, and mortality.
  • Emerging research indicates that aldosterone and salt also exert combined detrimental effects on target organs.

Purpose of the Study:

  • To elucidate the independent and combined roles of aldosterone and salt in cardiovascular health.
  • To explore clinical implications and potential interventions for mitigating aldosterone-salt interactions.

Main Methods:

  • Review of clinical studies examining aldosterone levels and dietary salt intake.
  • Analysis of the synergistic effects of aldosterone and salt on target-organ damage.
  • Evaluation of therapeutic strategies, including salt restriction and mineralocorticoid receptor antagonists.

Main Results:

  • Aldosterone and salt independently contribute to adverse cardiovascular outcomes.
  • Combined exposure to aldosterone and salt accelerates target-organ deterioration.
  • Reducing salt intake or blocking aldosterone can minimize these combined adverse effects.

Conclusions:

  • The interaction between aldosterone and salt has significant clinical implications for managing hypertension and cardiovascular disease.
  • Interventions targeting aldosterone (e.g., mineralocorticoid receptor antagonists, adrenalectomy) or salt intake are crucial.
  • Aldosterone reduction or blockade may also play a role in reducing salt appetite.